OncoMatch/Clinical Trials/NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Is NCT06284486 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Venetoclax and Revumenib for acute myeloid leukemia.
Treatment: Venetoclax · Revumenib — To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) rearrangement
Required: NPM1 mutation
Required: NUP98 rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
ECOG performance status of ≤ 2 (if aged ≥18 years); Karnofsky Performance Scale of ≥50 (if aged ≥16 years and <18 years); Lansky Performance Score of ≥50 (if aged <16 years)
Demographics
Prior therapy
Must have received: high intensity chemotherapy — first remission
first remission following high intensity chemotherapy
Must have received: hypomethylating agent — first remission
at least 2 cycles of low intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based)
Must have received: low-dose cytarabine-based — first remission
at least 2 cycles of low intensity therapy (e.g. hypomethylating agent or low-dose cytarabine-based)
Cannot have received: menin inhibitor
Prior treatment with a menin inhibitor
Lab requirements
Kidney function
estimated glomerular filtration rate ≥ 60 ml/min based on local institutional practice for age-appropriate determination
Liver function
direct bilirubin < 1.5x uln unless increase is due leukemic involvement, and ast and/or alt < 3x uln unless considered due to leukemic involvement, in which case direct bilirubin or ast and/or alt < 5x uln will be considered eligible
Cardiac function
baseline ejection fraction must be > 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University · Baltimore, Maryland
- Dana-Farber Cancer Center · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06284486 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior menin inhibitor disqualifies patients from enrollment.
Does this trial require KMT2A?
Yes, KMT2A rearrangement is a required biomarker for enrollment.
Does this trial require NPM1?
Yes, NPM1 mutation is a required biomarker for enrollment.
Does this trial require NUP98?
Yes, NUP98 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify